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Background
In an attempt to better treatment 
methodology for cervical cancer patients 
who are at higher risk for responding poorly 
to standard forms of treatment, research is 
being conducted to develop more targeted 
approaches to improve chances of recovery.
A potential factor worth investigating is the 
tumor microenvironment and how the 
diversity or presence of particular bacterium
may affect tumor response to treatment. 
Lactobacillus Iners has been identified as a 
species that may hinder a successful 
response of a tumor to chemoradiation 
treatment (CRT). This project seeks to 
investigate the validity of this specific 
effect.
Methods
• 8 Supernatants/Media Controls
• L.C. ATCC, L.C. Patient 39, L. Iners
ATCC, L. Iners Patient 370, L. Iners
Patient 366
• MRS (Control), NYCIII (Control), 
Media (Control)
• Cell Lines and Cisplatin Dosages Used
• HeLa: 0, 1, 2, 3, 4, 5 (ug/mL) 
(Removed after 1 hour)
• Cells Seeded: 100, 250, 500, 
750, 1000, 1500
• SiHa: 0, 0.15, 0.3, 0.45, 0.6, 0.75 
(ug/mL) (Removed after 4 hours)
• Cells Seeded: 100, 250, 500, 
750, 1000, 1500
• Incubation Periods
• HeLa: 10 days (7/9/21-7/19/21)
• SiHa: 14 days (7/8/21-7/22/21)
Results
For the HeLa cell line, colony formation of 
cells exposed to Lactobacillus Iners exhibited 
a smaller percent survival in comparison to 
cells treated with the negative media control, 
NYCIII. However, this slight trend is 
inconclusive as overlapping standard 
deviations suggest that the presence of L. 
Iners may not have a significant effect on cell 
recovery post treatment.
For the SiHa cell line, colony formation of 
cells exposed to Lactobacillus Iners also 
exhibited a smaller percent survival in 
comparison to the negative media control. 
However, large standard deviations again 
demonstrate that the presence of this bacteria 
in the tumor microbiome has a limited effect 
on the radio sensitization of tumor cells.
Interestingly, the difference in percent survival 
becomes significant at higher doses which 
may suggest that the sole presence of 
Lactobacillus Iners may actually heighten
radiosensitivity to cisplatin.
Conclusions
The sole presence of Lactobacillus Iners in the 
tumor microenvironment does not seem to 
have its hypothesized effect on the ability of 
cells to successfully respond to standard 
chemoradiation treatment. Cells treated with 
Lactobacillus Iners supernatant did not have a 
more pronounced recovery when compared to 
its negative media control. 
Future experimentation is needed to compare 
the difference between the presence of 
Lactobacillus Iners and Lactobacillus 
Crispatus in the tumor microbiome in addition 
to increased cell exposure to higher doses of 
cisplatin. Furthermore, clinical findings that 
suggest of a relationship between the presence 
of Lactobacillus Iners and decreased tumor 
radiosensitivity to chemotherapy may be a 
result of a combination of factors rather than 
the sole existence of Lactobacillus Iners in the
tumor microenvironment.
HeLa Clonogenic Assays: (0,1 ug/mL) 
Top Row: L. Iners ATCC and L. Iners Patient 370
Second Row: L. Iners Patient 366 and NYCIII (media ctrl.)
Third Row: Media (media control)
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Purpose & Hypothesis
The purpose of this project is to gain a better 
understanding of the relationship between 
the tumor microenvironment and its ability 
to influence tumor response to standard 
forms of treatment for cervical cancers. 
Understanding how the presence of different 
strains of bacteria influence the efficacy of 
chemotherapy will help improve the 
efficacy of treatment in future patients.  
We hypothesize that the presence of
Lactobacillus Iners supernatant will 
decrease the radiosensitivity of tumor cells 
to chemotherapy in both the HeLa and SiHa
cell lines.
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SiHa Clonogenic Assays: (0, 0.15 ug/mL) 
Top Row: L. Iners ATCC and L. Iners Patient 370
Second Row: L. Iners Patient 366 and NYCIII (media ctrl.)
Third Row: Media (media control)
Hela Clonogenic Assays: (0, 2 Gy) 
Top Row: NYCIII/L. Iners ATCC and L. Iners Patient 
370/366
Second Row: Media (media control)/MRS broth (media 
control) and L. Crispatus ATCC/366
